Diabetes Research Division, Department of Medicine
Hellerup, 2900, Denmark
Completed
NCT Number: NCT02104037
Liraglutide in Spinal Fluid
The purpose of this study is to investigate transfer of liraglutide from blood to cerebrospinal fluid.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Type 2 diabetes treated with liraglutide 1.8 mg for 1 month and 5% weight loss
Exclusion criteria
-
Treatment and study plan
Lumbar Puncture
ProcedurePrimary outcomes
-
cerebrospinal fluid concentration of liraglutide
Time frame: time 60 minutes
Sponsors and collaborators
Lead sponsor
Mikkel Christensen
Other
Registry information
Acronym: LIRA-CSV
Important dates
- Study start
- 2012
- Primary completion
- 2013
- First posted
- Apr 4, 2014
- Registry last updated
- Apr 4, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.